Testicular Tumor Markers in the Spermatic Vein - Correlation to Pathology, Stage and Outcome.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
08 2021
Historique:
received: 16 01 2021
revised: 14 03 2021
accepted: 01 04 2021
pubmed: 21 4 2021
medline: 10 2 2022
entrez: 20 4 2021
Statut: ppublish

Résumé

To report our findings in patients with determination of testicular tumor markers from the vena spermatica during inguinal orchiectomy. In a retrospective setting, data of patients who underwent inguinal orchiectomy between January 2004 and December 2014 were analyzed. Cubital and testicular vein tumor markers were assessed and correlated to histology, clinical stage and outcome. A total of 90 patients (seminomatous: n = 53, non-seminomatous: n = 37) with a median age of 37 years were included. The mean follow-up was 109 months. Overall, 60% (n = 54) of patients had one or more positive tumor marker level in the cubital vein vs 88.9% (n = 80) in the testicular vein. Median tumor marker levels of hCGβ in cubital and testicular vein were 1.9 U/l and 30.8U/l; the respective values for AFP were 2.9ng/ml and 2.4ng/ml and for hPLAP 49.9 mU/l and 418.9 mU/l. Differences in cubital vs testicular vein positivity were stage dependant and highest for pT1. Patients with seminomatous tumors had peripheral positivity of 59.3% vs 88.9% in the testicular vein (P = 0.003); in non-seminomatous patients the respective values were 61.1% and 88.9% (P = 0.02). All recurrent cancer patients under active surveillance (n = 5) were positive in the testicular vein. Virtually all testicular cancers shed tumor markers in the circulation. Differences in marker positivity (testicular vs testicular vein) were stage dependent (greatest in pT1), largely independent of histology and highest for hCGβ. The prognostic value of testicular vein sampling remains speculative.

Identifiants

pubmed: 33878332
pii: S0090-4295(21)00327-7
doi: 10.1016/j.urology.2021.04.003
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Chorionic Gonadotropin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-200

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Andreas Banner (A)

Department of Urology, Klinik Favoriten, Vienna, AUSTRIA.

Michael Lotterstätter (M)

Department of Urology, Klinik Favoriten, Vienna, AUSTRIA.

Stephan Madersbacher (S)

Department of Urology, Klinik Favoriten, Vienna, AUSTRIA; Sigmund Freud Private University, Vienna, AUSTRIA.

Ingrid Schauer (I)

Department of Urology, Klinik Favoriten, Vienna, AUSTRIA. Electronic address: ingrid_schauer@gmx.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH